← Back to screener

Cogent Biosciences, Inc. COGT

Rank #2321 · Nasdaq · $5.3B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
24.5
P/E
-27.5
P/B
20.73
ROE
-75.2%
Op. Margin
–%
Debt Ratio
28%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -27.5x, P/B 20.73x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -75.2%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 28%. Ranks in the top 16% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018$0.0B$-0.0B$-0.0B$-0.0B-312.8-84
2019$0.0B$-0.0B$-0.0B$-0.0B-369.9-53
2020$0.0B$-0.0B$-0.0B$0.1B-143.029
2021$0.0B$-0.1B$-0.1B$0.0B-1044.351
2022–$-0.1B$-0.1B$0.2B–8
2023–$-0.1B$-0.1B$0.2B–19
2024–$-0.1B$-0.1B$0.2B–26
2025–$-0.2B$-0.2B$0.3B–28

← See the full screener